SHL Telemedicine Ltd. announced the initial results from the Mayo Clinic HELP-MI and the Imperial College London TELE-ACS trials, presented at the V vulnerable Plaque and Patient Meeting (VPM) 2023 (as previously announced). The initial findings from both trials, which focus on the application of SHL's patented and FDA cleared SmartHeart®? 12-lead ECG technology for monitoring of post-MI (heart attack) patients at home, have been nothing short of remarkable.

Key highlights from the presentation of the initial results include: A staggering decrease of- 27.5% in emergency room visits in the TELE-ACS trial1. Moreover, hospital readmission rates soared by -55% in the TELE- ACS trial1. In the HELP-ME trial, cardiovascular-driven emergency department visits for patients using the SmartHeart®?

device were reduced to an astonishing 0 (zero)2. Cardiovascular driven rehospitalization was also at 0 (zero)2 for patients using the device in the HELP-ME trial. The presentation at the conference noted that the HELP-ME trial demonstrated the potential of SHL's system be successfully replicated in the US medical system, emphasizing its capability to reduce non-indicated cardiovascular emergency department visits and hospitalizations while improving early recognition of serious cardiovascular presentations.